With the therapeutic efficacy of current commercialized CAR-T cell therapies having been firmly established, attention has shifted to the lengthy and complex manufacturing process that currently limits their usage by driving up the cost of therapy while also prolonging critical delivery timelines to patients. Early pre-clinical studies indicate promise for a shorter manufacturing process that significantly decreases the manufacturing timeline to a 24-hour process. Innovative tools that allow for closure of the manufacturing process and minimization of manual touchpoints have helped streamline and eliminate manufacturing failures. Advancements in digital integration tools have also contributed to achievement of a more standardized manufacturing approach.
This webinar will provide viewers with: